These press releases are for business and financial media.
-
-
- Press release archive 2009
- 04 August 2009
- AstraZeneca And Astellas Enter Agreement for Co-Promotion of Symbicort Turbuhaler in Japan AstraZeneca and Astellas Pharma Inc. today announced an agreement for the co-promotion of AstraZeneca’s Symbicort Turbuhaler (budesonide/ formoterol, a dry powder inhaler), for the treatment of bronchial asthma in Japan.
-
-
-
- Press release archive 2009
- 01 August 2009
- FDA Approves ONGLYZA For The Treatment Of Type 2 Diabetes In The US AstraZeneca and Bristol-Myers Squibb today announced that the US Food and Drug Administration (FDA) has approved ONGLYZA (saxagliptin) for the treatment of type 2 diabetes mellitus in adults.
-
-
-
- Press release archive 2009
- 30 July 2009
- AstraZeneca PLC Second Quarter & Half Year Results 2009 AstraZeneca’s business performance, in the context of tough global economic conditions, has been better than anticipated. The strong first half performance is reflected in the increased Core EPS target for the full year and continued progress has been made on the pipeline.
-
-
-
- Press release archive 2009
- 09 July 2009
- AstraZeneca Terminates License Agreement with MAP Pharmaceuticals Regarding Unit Dose Budesonide AstraZeneca announced today that it has terminated the license agreement with MAP Pharmaceuticals, Inc., regarding Unit Dose Budesonide (UDB).
-
-
-
- Press release archive 2009
- 08 July 2009
- AstraZeneca to Advance AZD3480 in ADHD AstraZeneca plans to conduct further development of AZD3480 by initiating Phase IIb studies in attention deficit/hyperactivity disorder (ADHD) and has agreed to make a $10 million milestone payment to Targacept.
-
-
-
- Press release archive 2009
- 01 July 2009
- IRESSA (Gefitinib) Receives Marketing Authorisation for the Treatment of Non-Small Cell Lung Cancer in Europe AstraZeneca announced today that the European Commission has granted marketing authorisation for the oral anti-cancer drug, IRESSA for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK (epidermal growth factor receptor-tyrosine kinase) across all lines of therapy.
-
-
-
- Press release archive 2009
- 30 June 2009
- AstraZeneca Development Partner, Pozen, Inc., Submits New Drug Application for PN400 AstraZeneca today announced that its development partner, Pozen, Inc., has submitted a New Drug Application to the US Food and Drug Administration for VIMOVO (PN400) (enteric coated naproxen /esomeprazole magnesium) tablets, a product under investigation for the treatment of the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who are at risk of developing NSAID-associated ulcers.
-
-
-
- Press release archive 2009
- 25 June 2009
- ONGLYZA (saxagliptin) Receives Positive Opinion in Europe for the Treatment of Type 2 Diabetes AstraZeneca and Bristol-Myers Squibb Company today announced that their marketing authorisation application for ONGLYZA (saxagliptin) received a positive opinion from the Committee for Medicinal Products for Human Use for the treatment of type 2 diabetes in adults as add-on therapy with metformin, a thiazolidinedione or a sulphonylurea.
-
-
-
- Press release archive 2009
- 10 June 2009
- Favourable Vote from FDA Advisory Committee on Seroquel Paediatric Supplemental New Drug Applications On 10 June 2009, the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee conducted a review of the efficacy and safety of supplemental new drug applications (sNDAs) for SEROQUEL (quetiapine fumarate) proposed for the acute treatment of schizophrenia in adolescents (13-17 years of age), and the acute treatment of bipolar mania in children and adolescents (10-17 years of age).
-
-
-
- Press release archive 2009
- 04 June 2009
- AstraZeneca and Abbott Submit New Drug Application to the FDA for the Approval of CERTRIAD for the Treatment of Mixed Dyslipidemia AstraZeneca and Abbott announced today that the companies have submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational compound for the treatment of mixed dyslipidemia, a combination of two or more lipid abnormalities including high LDL cholesterol (the “bad” cholesterol), high triglycerides and low HDL-cholesterol (the “good” cholesterol).
-
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 09:09 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
